CoChat
Sign Up
Cited by 26Bone health and osteoporosis researchThyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Effects of Thyrotropin Suppression on Bone Health in Menopausal Women with Total Thyroidectomy

Open access
Kim, Eun Heui, Jeon, Yun Kyung, Pak, Kyoungjune, Kim, In-Joo, Kim, Seong-Jang, Shin, Seunghyeon, Kim, Bo Hyun, Kim, Sang Soo +4 more·2019·Journal of Bone Metabolism
DOI 10.11005/jbm.2019.26.1.31PMC PMC6416151
Open this paper in CoChat — free account

Abstract

BACKGROUND: This study examined the change in the trabecular bone score (TBS), areal bone mineral density (aBMD), and osteoporosis in postmenopausal women who underwent thyrotropin (TSH)-suppressive therapy for treating papillary thyroid cancer after a total thyroidectomy procedure. METHODS: We evaluated 36 postmenopausal women who received a total thyroidectomy for papillary thyroid cancer and were undergoing TSH suppressive therapy with levothyroxine. Postmenopausal women (n=94) matched for age and body mass index were recruited as healthy controls. The aBMD and TBS of the lumbar spine were compared between dual energy X-ray absorptiometry (DXA) at baseline and at follow-up after an average of 4.92 years. RESULTS: <0.001). The TBS and aBMD did not differ significantly between the initial and follow-up DXA images in both groups of TSH suppressive patients and controls. CONCLUSIONS: The average value of TBS and aBMD did not significantly change during the follow-up period. The TSH suppressive therapy was revealed as not a significant factor for the progressive deterioration of bone status during long term follow-up.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.11005/jbm.2019.26.1.31

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In pre- and postmenopausal women receiving LT4 treatment, there were no significant changes in BMD and trabecular bone score.

    “These findings are consistent with some studies that focused on pre- and postmenopausal women receiving LT4 treatment, which reported no significant changes in BMD and trabecular bone score [48, 49].”

    From Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis (2025) · cites this paper as [48]

    The Methods identify the study participants as postmenopausal women receiving TSH-suppressive LT4. The Results report no significant change in their aBMD or trabecular bone score between baseline and follow-up. This study did not test that finding in premenopausal women; the Discussion mentions a separate study including premenopausal women, but describes its BMD result, not a trabecular bone score result. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. [1]Abe E Marians RC Yu W TSH is a negative regulator of skeletal remodeling Cell 2003 115 151 162 14567913
  2. [2]Sendak RA Sampath TK McPherson JM Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling Int Orthop 2007 31 753 757 17611756 PMC2266660
  3. [4]Mosekilde L Melsen F Bagger JP Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism Acta Endocrinol (Copenh) 1977 85 515 525 577336
  4. [5]Biondi B Cooper DS Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer Thyroid 2010 20 135 146 20151821
  5. [6]Cady B Cohn K Rossi RL The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma Surgery 1983 94 978 983 6648813
  6. [8]Flynn RW Bonellie SR Jung RT Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy J Clin Endocrinol Metab 2010 95 186 193 19906785
  7. [9]de Melo TG da Assumpção LV Santos Ade O Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma Thyroid Res 2015 8 7 26097507 PMC4474343
  8. [11]Ross DS Neer RM Ridgway EC Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine Am J Med 1987 82 1167 1170 3605133
  9. [12]Ross DS Hyperthyroidism, thyroid hormone therapy, and bone Thyroid 1994 4 319 326 7833670
  10. [13]Solomon BL Wartofsky L Burman KD Prevalence of fractures in postmenopausal women with thyroid disease Thyroid 1993 3 17 23 8499760
  11. [14]Grimnes G Emaus N Joakimsen RM The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromso study Thyroid 2008 18 1147 1155 18925834
  12. [15]Wang LY Smith AW Palmer FL Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma Thyroid 2015 25 300 307 25386760 PMC6916125
  13. [16]Pothuaud L Carceller P Hans D Correlations between greylevel variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture Bone 2008 42 775 787 18234577
  14. [17]Lee JE Kim KM Kim LK Comparisons of TBS and lumbar spine BMD in the associations with vertebral fractures according to the T-scores: a cross-sectional observation Bone 2017 105 269 275 28963079
  15. [19]Moon JH Kim KM Oh TJ The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma J Clin Endocrinol Metab 2017 102 78 85 27754806
  16. [20]Silva BC Bilezikian JP Trabecular bone score: perspectives of an imaging technology coming of age Arq Bras Endocrinol Metabol 2014 58 493 503 25166040
  17. [21]Cooper DS Doherty GM Haugen BR Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 2009 19 1167 1214 19860577
  18. [22]Biondi B Filetti S Schlumberger M Thyroid-hormone therapy and thyroid cancer: a reassessment Nat Clin Pract Endocrinol Metab 2005 1 32 40 16929364
  19. [23]Pacini F Schlumberger M Dralle H European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 2006 154 787 803 16728537
  20. [24]Balme HW Metastatic carcinoma of the thyroid successfully treated with thyroxine Lancet 1954 266 812 813 13153121
  21. [25]McGriff NJ Csako G Gourgiotis L Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer Ann Med 2002 34 554 564 12553495
  22. [26]Sugitani I Fujimoto Y Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study Surgery 2011 150 1250 1257 22136848
  23. [27]Kung AW Yeung SS Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin J Clin Endocrinol Metab 1996 81 1232 1236 8772604
  24. [28]Heemstra KA Hamdy NA Romijn JA The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma Thyroid 2006 16 583 591 16839260
  25. [29]Quan ML Pasieka JL Rorstad O Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature J Surg Oncol 2002 79 62 69 11754378
  26. [30]Lee MY Park JH Bae KS Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer Ann Surg Treat Res 2014 86 55 60 24761409 PMC3994597
  27. [31]Franklyn JA Betteridge J Daykin J Long-term thyroxine treatment and bone mineral density Lancet 1992 340 9 13 1351654
  28. [32]Kim CW Hong S Oh SH Change of bone mineral density and biochemical markers of bone turnover in patients on suppressive levothyroxine therapy for differentiated thyroid carcinoma J Bone Metab 2015 22 135 141 26389089 PMC4572035
  29. [33]WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group World Health Organ Tech Rep Ser 1994 843 1 129 7941614
  30. [34]Leslie WD Johansson H Kanis JA Lumbar spine texture enhances 10-year fracture probability assessment Osteoporos Int 2014 25 2271 2277 24951032
  31. [35]Bousson V Bergot C Sutter B Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects Osteoporos Int 2012 23 1489 1501 22083541
  32. [36]Sampath TK Simic P Sendak R Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats J Bone Miner Res 2007 22 849 859 17352644
  33. [37]Kim HY Mohan S Role and mechanisms of actions of thyroid hormone on the skeletal development Bone Res 2013 1 146 161 26273499 PMC4472099
  34. [38]Kim MK Yun KJ Kim MH The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma Bone 2015 71 101 105 25445448

Cited by

Sorted by citations

Authors
Kim, E. H., Jeon, Y. K., Pak, K., Kim, I.-J., Kim, S.-J., Shin, S., Kim, B. H., Kim, S. S., Lee, B.-J., Lee, J.-G., Goh, T. S., & Kim, K.
Affiliations
  • Pusan National University Hospital (KR)
  • Pusan National University (KR)
  • Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
ORCID
Venue
Journal of Bone Metabolism
Publisher
Korean Society for Bone and Mineral Research
Published
2019
Volume
26
Issue
1
Pages
31
ISSN
  • 2287-6375 (ISSN-L)
  • 2287-7029
DOI
10.11005/jbm.2019.26.1.31
PMC
PMC6416151
OpenAlex
W2920863879
Cited by
26
References
4
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 2
FWCI
3.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Bone Metabolism (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Ministry of Science, ICT and Future Planning
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
TSH suppression, bone health, trabecular bone score, areal bone mineral density, osteoporosis, postmenopausal women, total thyroidectomy, papillary thyroid carcinoma, levothyroxine, lumbar spine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review